Who are Hib-MenAC mixed with Tritanrix™-HepB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sIPV+DTaP+HepA, TDaP-IPV vaccine, sIPV+DTaP+MMR, Boostrix TM, Infanrix TM, Pentacel (DPTaP+Hib).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hib-menac-mixed-with-tritanrix-hepb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hib-MenAC mixed with Tritanrix™-HepB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hib-MenAC mixed with Tritanrix™-HepB (Hib-MenAC mixed with Tritanrix™-HepB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology / Infectious Disease.

phase 3 Combination vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Hib-MenAC mixed with Tritanrix™-HepB (Hib-MenAC mixed with Tritanrix™-HepB) — GlaxoSmithKline. This combination vaccine stimulates immune responses against Haemophilus influenzae type b, Neisseria meningitidis serogroups A and C, diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis through antigen presentation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Hib-MenAC mixed with Tritanrix™-HepB TARGET	Hib-MenAC mixed with Tritanrix™-HepB	GlaxoSmithKline	phase 3	Combination vaccine
sIPV+DTaP+HepA	sIPV+DTaP+HepA	China National Biotec Group Company Limited	marketed	Combination vaccine
TDaP-IPV vaccine	TDaP-IPV vaccine	Radboud University Medical Center	marketed	combination vaccine
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine
Boostrix TM	Boostrix TM	GlaxoSmithKline	marketed	Combination vaccine (toxoid and acellular pertussis)
Infanrix TM	Infanrix TM	GlaxoSmithKline	marketed	Inactivated combination vaccine
Pentacel (DPTaP+Hib)	Pentacel (DPTaP+Hib)	The Hospital for Sick Children	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

GlaxoSmithKline · 22 drugs in this class
Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
Serum Institute of India Pvt. Ltd. · 3 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Sanofi · 3 drugs in this class
PT Bio Farma · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hib-MenAC mixed with Tritanrix™-HepB — Competitive Intelligence Brief. https://druglandscape.com/ci/hib-menac-mixed-with-tritanrix-hepb. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab